FATE - Fate Therapeutics GAAP EPS of -$0.68 beats by $0.11 revenue of $18.4M beats by $9.39M May, 04 2022 04:05 PM Fate Therapeutics Inc. Fate Therapeutics press release (NASDAQ:FATE): Q1 GAAP EPS of -$0.68 beats by $0.11. Revenue of $18.4M (+65.2% Y/Y) beats by $9.39M. For further details see: Fate Therapeutics GAAP EPS of -$0.68 beats by $0.11, revenue of $18.4M beats by $9.39M